{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"80.6","value":"25"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"97.5","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"60.2","value":"0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"33.6","value":"0"},{"groupId":"OG006","lowerLimit":"0.1","upperLimit":"16.2","value":"3"},{"groupId":"OG007","lowerLimit":"0.3","upperLimit":"48.2","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Overall Response Rate-Part 1 QD","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}